Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomotrelvir in nonhospitalized symptomatic adults with COVID-19
NCT05543707Phase 2Terminated
- Sponsor
- Pardes Biosciences
- Start
- Sep 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pomotrelvir in coronavirus disease 2019 (COVID-19), sponsored by Pardes Biosciences. Started Sep 2022; status: terminated.
02
Drugs
pomotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05543707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05543707.